Alkermes Plc (ALKS) 49.56 $ALKS Alkermes (ALKS) Posts

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alkermes Plc (ALKS) 49.56 $ALKS

Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:06AM CDT
Alkermes (ALKS) reported a narrower-than-expected, second-quarter 2016 loss while revenues beat estimates; the company revised its outlook for 2016.
INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), ALKS: 49.56 (-0.34)

Alkermes Falls 7.07% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 28, 2:59PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $47.23 to a high of $51.50. Yesterday, the shares fell 7.1%, which took the trading range below the 3-day low of $49.28 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALKS: 49.56 (-0.34)

Alkermes plc Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Jul 28, 6:00AM CDT
---- Company Improves Financial Expectations for 2016 Driven by Strong VIVITROL(R) Performance --
ALKS: 49.56 (-0.34)

38.7% Return Seen to Date on SmarTrend Alkermes Call (ALKS)
Comtex SmarTrend(R) - Thu Jul 28, 12:28AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 4 months, Alkermes has returned 38.75% as of today's recent price of $51.78.
ALKS: 49.56 (-0.34)

Upgrade Alert for Alkermes (ALKS)
Comtex SmarTrend(R) - Wed Jul 27, 3:25AM CDT
Alkermes (NASDAQ:ALKS) was upgraded from Market Perform to Outperform at Cowen and Company today. The stock closed yesterday at $51.01 on volume of 822,000 shares, below average daily volume of 1.4 million. Over the past year, Alkermes has traded in a range of $27.14 to $80.71 and closed yesterday at $51.01, 88% above that low. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.1% while the 200-day MA has slid 1.1%.
ALKS: 49.56 (-0.34)

Healthcare Sector Equities Under Review -- Intrexon, Alkermes, BioScrip, and Heartware Intl.
PR Newswire - Tue Jul 26, 7:50AM CDT
The Healthcare sector presents some of the most profitable trades in the market, but challenges, such as ransom-ware risks, demand pressures, and cost issues, continue to persist. Today, Stock-Callers.com presents these four companies for further assessment: Intrexon Corp. (NYSE: XON), Alkermes PLC (NASDAQ: ALKS), BioScrip Inc. (NASDAQ: BIOS), and Heartware International Inc. (NASDAQ: HTWR). Learn more about these stocks by accessing their freenotes at:
XON: 27.38 (+2.05), BIOS: 2.58 (+0.02), HTWR: 57.96 (+0.02), ALKS: 49.56 (-0.34)

Alkermes Has Returned 31.4% Since SmarTrend Recommendation (ALKS)
Comtex SmarTrend(R) - Wed Jul 13, 12:45AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 3 months, Alkermes has returned 31.43% as of today's recent price of $49.05.
ALKS: 49.56 (-0.34)

Look for Shares of Alkermes to Potentially Pullback after Yesterday's 4.17% Rise
Comtex SmarTrend(R) - Thu Jul 07, 2:57PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.99 to a high of $47.91. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $46.23 on volume of 508,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.56 (-0.34)

After Yesterday's Rally of 3.42% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 22, 3:05PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $41.29 to a high of $44.00. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $42.81 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.56 (-0.34)

23.0% Return Seen to Date on SmarTrend Alkermes Call (ALKS)
Comtex SmarTrend(R) - Wed Jun 08, 1:28AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 2 months, Alkermes has returned 22.96% as of today's recent price of $45.89.
ALKS: 49.56 (-0.34)

Alkermes' Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Wed Jun 01, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016, at 1:20 p.m. PDT (4:20 p.m. EDT/9:20 p.m. BST) from the Terranea Resort in Rancho Palos Verdes, Calif. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 49.56 (-0.34)

Shares of ALKS Up 24.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 01, 1:09AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 2 months, Alkermes has returned 24.36% as of today's recent price of $46.41.
ALKS: 49.56 (-0.34)

SmarTrend Watching for Potential Pullback in Shares of Alkermes After 1.89% Gain
Comtex SmarTrend(R) - Tue May 31, 4:34PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.99 to a high of $47.90. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $46.21 on volume of 692,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.56 (-0.34)

Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15), ALKS: 49.56 (-0.34)

Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors
BusinessWire - Thu May 26, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L. Snyderman, M.D., to the company's Board of Directors. Dr. Snyderman most recently served as Chief Medical Editor at NBC News, and has more than three decades of experience as a leading voice in healthcare and medicine. Dr. Snyderman is a board certified Otolaryngologist-Head and Neck Surgeon and Fellow in the American College of Surgeons.
ALKS: 49.56 (-0.34)

Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230
BusinessWire - Wed May 25, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA(TM)) protein designed for targeted interleukin-2 (IL-2) receptor activation. The multi-center phase 1 study is designed to evaluate the safety, tolerability and immunological-pharmacodynamic effects of ALKS 4230 in the treatment of patients with solid tumors.
ALKS: 49.56 (-0.34)

Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
BusinessWire - Tue May 24, 6:00AM CDT
---- Management Will Discuss Data and Study Design Details From FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 for the Treatment of Major Depressive Disorder --
ALKS: 49.56 (-0.34)

SmarTrend Watching for Potential Pullback in Shares of Alkermes After 7.46% Gain
Comtex SmarTrend(R) - Fri May 20, 2:01PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $39.36 to a high of $42.84. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $41.13 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 49.56 (-0.34)

Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 0.27 (+0.02), AMAG: 27.02 (+0.49), IDXX: 93.51 (-0.28), ALKS: 49.56 (-0.34)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 156

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 129

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 156

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 199

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 111

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 171

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 85

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 41

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 277

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

Olo Inc. Under Investigation for Potential Fiduciary Violations

Updated Category News Views 255

Olo Inc. Faces Investigation Over Fiduciary Duties Olo Inc. is currently under investigation by legal authorities due to possible breaches of fiduciary duty by its directors and management. This scrutiny follows Olo's announcement regarding a major acquisition deal with investment firm Thoma Bravo, valued at around $2 billion. Details of the Investigation The focus of the...

Continue Reading
Join MT Højgaard Holding's Conference Call on FY 2024 Results

Updated Category News Views 115

MT Højgaard Holding A/S Conference Call Overview MT Højgaard Holding is set to release its annual report for the fiscal year 2024 on a chosen date. Following this release, a conference call will take place where the management team will delve into the company’s performance and projections for the future. This session aims to provide insights into the results for the...

Continue Reading
ClearValue Consulting Partners with Restb.ai for Advanced Appraisals

Updated Category News Views 77

Unlocking Efficiency in Appraisal Reviews ClearValue Consulting, a leader in innovative valuation solutions, has announced an exciting new partnership with Restb.ai, a prominent name in AI-powered computer vision. This collaboration is set to redefine the appraisal review landscape, bringing in advanced technologies to streamline processes and enhance quality. The Impact...

Continue Reading
BrightSphere's Transformation: New Name and Leadership Direction

Updated Category News Views 393

BrightSphere Investment Group Inc. (NYSE: BSIG) announced its rebranding to Acadian Asset Management back in early 2025, marking a major shift in strategy. This wasn't just a name change; it was the end of their multi-boutique model and the start of a more streamlined focus on asset management. They offloaded six out of seven affiliates to zero in on core...

Continue Reading
Why Super Micro Computer’s Growth Could Still Continue

Updated Category News Views 339

Super Micro Computer (NASDAQ: SMCI) kicked off 2024 like a rocket, watching its stock explode by an eye-popping 188% in the first half. It was a remarkable performance that even left tech giants scrambling for a second look. The surge stemmed largely from surging demand for their cutting-edge workstations and servers—essential cogs in the booming artificial intelligence...

Continue Reading